Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,830 | 1,890 | 19:03 | |
1,790 | 1,940 | 21.02. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
---|---|---|---|---|
08.01. | Cocrystal Pharma, Inc. - 8-K, Current Report | 5 | SEC Filings | |
31.12.24 | Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide | 1 | Benzinga.com | |
31.12.24 | Cocrystal stock plunges 40% on influenza drug update | 2 | Seeking Alpha | |
31.12.24 | Cocrystal Pharma verlängert Studie aufgrund niedriger Grippeinfektionsrate | 8 | Investing.com Deutsch | |
31.12.24 | Cocrystal Pharma extends trial due to low flu infection rate | 1 | Investing.com | |
31.12.24 | Cocrystal Pharma, Inc.: Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 | 150 | GlobeNewswire (Europe) | |
31.12.24 | Cocrystal Pharma, Inc. - 8-K, Current Report | - | SEC Filings | |
COCRYSTAL Aktie jetzt für 0€ handeln | ||||
27.12.24 | COCP-Aktie erreicht 52-Wochen-Hoch bei 3,1 US-Dollar | 10 | Investing.com Deutsch | |
13.11.24 | Cocrystal Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | |
13.11.24 | Cocrystal Pharma GAAP EPS of -$0.49 beats by $0.08 | 2 | Seeking Alpha | |
13.11.24 | Cocrystal Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | |
31.10.24 | Cocrystal Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | |
10.10.24 | Cocrystal Pharma-Führungskräfte erhalten Gehaltserhöhung und Aktien-Zuteilungen | 7 | Investing.com Deutsch | |
10.10.24 | Cocrystal Pharma execs get pay raise and stock grants | 1 | Investing.com | |
10.10.24 | Cocrystal Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | |
26.09.24 | Cocrystal Pharma startet nächste Phase der antiviralen Studie | 2 | Investing.com Deutsch | |
15.08.24 | CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event | 396 | ACCESS Newswire | |
18.07.24 | Cocrystal Pharma, Inc.: Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor | 143 | GlobeNewswire (Europe) | |
20.06.24 | Cocrystal Pharma, Inc.: New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows | 186 | GlobeNewswire (Europe) | |
13.05.24 | Cocrystal Pharma, Inc.: Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs | 161 | GlobeNewswire (Europe) |